{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:55:54Z","timestamp":1794639354380,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Erasmus MC Fellowship grant","id":[{"id":"https:\/\/ror.org\/018906e22","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Young Investigator Bas Mulder Award of Dutch Cancer Society","award":["12013\/2018-2"],"award-info":[{"award-number":["12013\/2018-2"]}],"id":[{"id":"https:\/\/ror.org\/0368jnd28","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Four Dutch health insurance companies"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The introduction of programmed cell death protein 1 (PD-1) blockers (i.e. nivolumab and pembrolizumab) has significantly improved the prognosis of patients with advanced melanoma. However, the long treatment duration (i.e. two years or longer) has a high impact on patients and healthcare systems in terms of (severe) toxicity, health-related quality of life (HRQoL), resource use, and healthcare costs. While durable tumour responses have been observed and PD-1 blockade is discontinued on an individual basis, no consensus has been reached on the optimal treatment duration. The objective of the Safe Stop trial is to evaluate whether early discontinuation of first-line PD-1 blockade is safe in patients with advanced and metastatic melanoma who achieve a radiological response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Safe Stop trial is a nationwide, multicentre, prospective, single-arm, interventional study in the Netherlands. A total of 200 patients with advanced and metastatic cutaneous melanoma and a confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumours (RECIST) v1.1 will be included to early discontinue first-line monotherapy with nivolumab or pembrolizumab. The primary objective is the rate of ongoing responses at 24\u00a0months after discontinuation of PD-1 blockade. Secondary objectives include best overall and duration of response, need and outcome of rechallenge with PD-1 blockade, and changes in (serious) adverse events and HRQoL. The impact of treatment discontinuation on healthcare resource use, productivity losses, and hours of informal care will also be assessed. Results will be compared to those from patients with CR or PR who completed 24\u2009months of treatment with PD-1 blockade and had an ongoing response at treatment discontinuation. It is hypothesised that it is safe to early stop first-line nivolumab or pembrolizumab at confirmed tumour response while improving HRQoL and reducing costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>From a patient, healthcare, and economic perspective, shorter treatment duration is preferred and overtreatment should be prevented. If early discontinuation of first-line PD-1 blockade appears to be safe, early discontinuation of PD-1 blockade may be implemented as the standard of care in a selected group of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      The Safe Stop trial has been registered in the Netherlands Trial Register (NTR), Trial NL7293 (old NTR ID: 7502),\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.trialregister.nl\/trial\/7293\">https:\/\/www.trialregister.nl\/trial\/7293<\/jats:ext-link>\n                      . Date of registration September 30, 2018.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08018-w","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T17:02:54Z","timestamp":1616691774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial"],"prefix":"10.1186","volume":"21","author":[{"given":"E. E. A. P.","family":"Mulder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"de Joode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Liti\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"ten Tije","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. P. M.","family":"Suijkerbuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Boers-Sonderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. A. P.","family":"Hospers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W. B.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J. M.","family":"van den Eertwegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J. B.","family":"Aarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Piersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. S.","family":"van Rijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Vreugdenhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. W. P. J.","family":"van den Berkmortel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Oomen-de","family":"Hoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"Franken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ryll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. B. A. G.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A. M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"issue":"6","key":"8018_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrc.2016.37","volume":"16","author":"AH Shain","year":"2016","unstructured":"Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer. 2016;16(6):345\u201358. https:\/\/doi.org\/10.1038\/nrc.2016.37.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"8018_CR2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc.2017.43","volume":"17","author":"R Ossio","year":"2017","unstructured":"Ossio R, Roldan-Marin R, Martinez-Said H, Adams DJ, Robles-Espinoza CD. Melanoma: a global perspective. Nat Rev Cancer. 2017;17(7):393\u20134. https:\/\/doi.org\/10.1038\/nrc.2017.43.","journal-title":"Nat Rev Cancer"},{"issue":"Suppl 6","key":"8018_CR3","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/annonc\/mdp252","volume":"20","author":"RM MacKie","year":"2009","unstructured":"MacKie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Ann Oncol. 2009;20(Suppl 6):vi1\u20137.","journal-title":"Ann Oncol"},{"issue":"36","key":"8018_CR4","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199\u2013206. https:\/\/doi.org\/10.1200\/JCO.2009.23.4799.","journal-title":"J Clin Oncol"},{"issue":"9","key":"8018_CR5","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(19)30388-2.","journal-title":"Lancet Oncol"},{"issue":"16","key":"8018_CR6","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1910836.","journal-title":"N Engl J Med"},{"issue":"7","key":"8018_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with Dabrafenib plus Trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1904059.","journal-title":"N Engl J Med"},{"key":"8018_CR8","unstructured":"Rahul S, Hans M, Varinder K, et al. Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol. 0(0):JCO.20.00198."},{"issue":"1","key":"8018_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/jcm9010223","volume":"9","author":"FF Gellrich","year":"2020","unstructured":"Gellrich FF, Schmitz M, Beissert S, Meier F. Anti-PD-1 and novel combinations in the treatment of melanoma-an update. J Clin Med. 2020;9(1):223. https:\/\/doi.org\/10.3390\/jcm9010223.","journal-title":"J Clin Med"},{"key":"8018_CR10","doi-asserted-by":"crossref","unstructured":"Leeneman B, Uyl-de Groot CA, Aarts MJB et al. Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. Cancers. 2020;12:1003.","DOI":"10.3390\/cancers12041003"},{"issue":"4","key":"8018_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1412082.","journal-title":"N Engl J Med"},{"key":"8018_CR12","doi-asserted-by":"crossref","unstructured":"Davies MA. Is It Safe to Stop Anti\u2013PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response? J Clin Oncol. 2020;38:1645\u20137.","DOI":"10.1200\/JCO.20.00136"},{"issue":"14","key":"8018_CR13","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, , et al: Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 2017, 377(14):1345\u20131356, DOI: https:\/\/doi.org\/10.1056\/NEJMoa1709684.","journal-title":"N Engl J Med"},{"key":"8018_CR14","doi-asserted-by":"crossref","unstructured":"Hsieh AH-C, Faithfull S, Brown MP. Risk of cumulative toxicity after complete melanoma response with pembrolizumab. BMJ Case Reports. 2017;2017:bcr2016218308.","DOI":"10.1136\/bcr-2016-218308"},{"issue":"10","key":"8018_CR15","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020\u201330. https:\/\/doi.org\/10.1200\/JCO.2013.53.0105.","journal-title":"J Clin Oncol"},{"key":"8018_CR16","doi-asserted-by":"crossref","unstructured":"Robert C, Ribas A, Hamid O et al. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol. 2017;36:1668\u201374.","DOI":"10.1200\/JCO.2017.75.6270"},{"key":"8018_CR17","doi-asserted-by":"crossref","unstructured":"Rosner S, Bogatch K, Postow MA. Outcomes of patients with melanoma who discontinue immunotherapy. J Clin Oncol. 2017;35:9548.","DOI":"10.1200\/JCO.2017.35.15_suppl.9548"},{"issue":"15_suppl","key":"8018_CR18","doi-asserted-by":"publisher","first-page":"9504","DOI":"10.1200\/JCO.2017.35.15_suppl.9504","volume":"35","author":"C Robert","year":"2017","unstructured":"Robert C, Long GV, Schachter J, et al. Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment. J Clin Oncol. 2017;35(15_suppl):9504.","journal-title":"J Clin Oncol"},{"issue":"4","key":"8018_CR19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz011.","journal-title":"Ann Oncol"},{"issue":"34","key":"8018_CR20","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","volume":"35","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with Nivolumab and Ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. 2017;35(34):3807\u201314. https:\/\/doi.org\/10.1200\/JCO.2017.73.2289.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8018_CR21","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","volume":"145","author":"A Indini","year":"2019","unstructured":"Indini A, Di Guardo L, Cimminiello C, et al. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol. 2019;145(2):511\u201321. https:\/\/doi.org\/10.1007\/s00432-018-2819-x.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"8018_CR22","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(18)30700-9.","journal-title":"Lancet Oncol"},{"issue":"6","key":"8018_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M, et al. Immune checkpoint inhibitor Rechallenge after immune-related adverse events in patients with Cancer. JAMA Oncol. 2020;6(6):1\u20137.","journal-title":"JAMA Oncol"},{"issue":"5","key":"8018_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/ddg.14091","volume":"18","author":"R Reschke","year":"2020","unstructured":"Reschke R, Ziemer M. Rechallenge with checkpoint inhibitors in metastatic melanoma. J Dtsch Dermatol Ges. 2020;18(5):429\u201336. https:\/\/doi.org\/10.1111\/ddg.14091.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"7","key":"8018_CR25","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/annonc\/mdz110","volume":"30","author":"YJL Jansen","year":"2019","unstructured":"Jansen YJL, Rozeman EA, Mason R, et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol. 2019;30(7):1154\u201361. https:\/\/doi.org\/10.1093\/annonc\/mdz110.","journal-title":"Ann Oncol"},{"issue":"20","key":"8018_CR26","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.1158\/1078-0432.CCR-18-1311","volume":"24","author":"AB Warner","year":"2018","unstructured":"Warner AB, Postow MA. Bigger is not always better: tumor size and prognosis in advanced melanoma. Clin Cancer Res. 2018;24(20):4915\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1311.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"8018_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","volume":"1","author":"J Larkin","year":"2015","unstructured":"Larkin J, Lao CD, Urba WJ, et al. Efficacy and safety of nivolumab in patients with braf v600 mutant and braf wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncology. 2015;1(4):433\u201340. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1184.","journal-title":"JAMA Oncology"},{"issue":"11","key":"8018_CR28","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1200\/JCO.2016.69.6336","volume":"35","author":"CG Kohn","year":"2017","unstructured":"Kohn CG, Zeichner SB, Chen Q, et al. Cost-effectiveness of immune checkpoint inhibition in BRAF wild-type advanced melanoma. J Clin Oncol. 2017;35(11):1194\u2013202. https:\/\/doi.org\/10.1200\/JCO.2016.69.6336.","journal-title":"J Clin Oncol"},{"issue":"4","key":"8018_CR29","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559\u201374. https:\/\/doi.org\/10.1093\/annonc\/mdv623.","journal-title":"Ann Oncol"},{"issue":"suppl_4","key":"8018_CR30","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"J Haanen","year":"2017","unstructured":"Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119\u201342.","journal-title":"Ann Oncol"},{"issue":"2","key":"8018_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368. https:\/\/doi.org\/10.1056\/NEJMra1703481.","journal-title":"N Engl J Med"},{"issue":"7","key":"8018_CR32","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou S, Yang F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008\u201319. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0393.","journal-title":"JAMA Oncol"},{"issue":"7","key":"8018_CR33","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/annonc\/mdw174","volume":"27","author":"M Chatterjee","year":"2016","unstructured":"Chatterjee M, Turner DC, Felip E, et al. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol. 2016;27(7):1291\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdw174.","journal-title":"Ann Oncol"},{"issue":"2","key":"8018_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"8","key":"8018_CR35","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/j.1524-4733.2009.00570.x","volume":"12","author":"RL Askew","year":"2009","unstructured":"Askew RL, Xing Y, Palmer JL, et al. Evaluating minimal important differences for the FACT-melanoma quality of life questionnaire. Value Health. 2009;12(8):1144\u201350. https:\/\/doi.org\/10.1111\/j.1524-4733.2009.00570.x.","journal-title":"Value Health"},{"issue":"4","key":"8018_CR36","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jval.2016.11.015","volume":"20","author":"NS McClure","year":"2017","unstructured":"McClure NS, Sayah FA, Xie F, et al. Instrument-defined estimates of the minimally important difference for EQ-5D-5L index scores. Value Health. 2017;20(4):644\u201350. https:\/\/doi.org\/10.1016\/j.jval.2016.11.015.","journal-title":"Value Health"},{"issue":"1","key":"8018_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-5-70","volume":"5","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5(1):70. https:\/\/doi.org\/10.1186\/1477-7525-5-70.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"8018_CR38","doi-asserted-by":"publisher","first-page":"E44","DOI":"10.1097\/NCC.0b013e3182813a17","volume":"37","author":"JA Custers","year":"2014","unstructured":"Custers JA, van den Berg SW, van Laarhoven HW, et al. The Cancer worry scale: detecting fear of recurrence in breast cancer survivors. Cancer Nurs. 2014;37(1):E44\u201350. https:\/\/doi.org\/10.1097\/NCC.0b013e3182813a17.","journal-title":"Cancer Nurs"},{"issue":"6","key":"8018_CR39","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jval.2015.05.009","volume":"18","author":"C Bouwmans","year":"2015","unstructured":"Bouwmans C, Krol M, Severens H, et al. The iMTA productivity cost questionnaire: a standardized instrument for measuring and valuing health-related productivity losses. Value Health. 2015;18(6):753\u20138. https:\/\/doi.org\/10.1016\/j.jval.2015.05.009.","journal-title":"Value Health"},{"issue":"1","key":"8018_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","volume":"38","author":"R Brookmeyer","year":"1982","unstructured":"Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38(1):29\u201341. https:\/\/doi.org\/10.2307\/2530286.","journal-title":"Biometrics"},{"key":"8018_CR41","volume-title":"Survival analysis: techniques for censored and truncated data: Springer Science & Business Media","author":"JP Klein","year":"2006","unstructured":"Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data: Springer Science & Business Media; 2006."},{"key":"8018_CR42","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejca.2016.11.021","volume":"72","author":"A Jochems","year":"2017","unstructured":"Jochems A, Schouwenburg MG, Leeneman B, et al. Dutch melanoma treatment registry: quality assurance in the care of patients with metastatic melanoma in the Netherlands. Eur J Cancer. 2017;72:156\u201365. https:\/\/doi.org\/10.1016\/j.ejca.2016.11.021.","journal-title":"Eur J Cancer"},{"issue":"3","key":"8018_CR43","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8.","journal-title":"Lancet Oncol"},{"key":"8018_CR44","doi-asserted-by":"crossref","unstructured":"de Joode K, Dumoulin DW, Tol J et al. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. Eur J Cancer. 2020;141:171\u201384.","DOI":"10.1016\/j.ejca.2020.09.027"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08018-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-021-08018-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08018-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T17:08:56Z","timestamp":1616692136000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08018-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8018"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08018-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"19 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Erasmus Medical Centre Ethics Committee (ref. no. MEC-2018-114). The study will be conducted according to the principles of the Declaration of Helsinki (10th version, Fortaleza 2013) and in concordance with the Dutch Medical Research Improving Human Subjects Act and other applicable guidelines, regulations, and acts. In compliance with the International Conference on Harmonisation Good Clinical Practice and other applicable regulations, patients will be informed and asked for written informed consent by their treating physician, local investigators, or research nurse at one of the participating hospitals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author-specific disclosures: KS: Honoraria: Novartis, Roche, MSD Oncology. Advisory board: Novartis, MSD, BMS, Pierre Fabre, Abbvie. All paid to the institution. MB: consultant and\/or advisory board member: BMS, Novartis, Merck, Pierre Fabre. GH: consultant and\/or advisory board member: Amgen, Roche, MSD, BMS, Pfizer, Novartis, Pierre Fabry. Research grant: BMS, Seerave. All paid to the institution. JG: Consultant and\/or advisory board member: BMS, MSD, Pierre Fabre, Servier. AE: Study grant: Sanofi, Roche, BMS, TEVA, Idera. Travel expenses: MSD Oncology, Roche, Pfizer, Sanofi. Speaker Honoraria: Bristol-Myers Squibb, Novartis. Advisory Board: BMS, MSD Oncology, Amgen, Roche, Novartis, Sanofi, Pfizer, Ipsen, Merck, Pierre Fabre. MA: Consultant and\/or advisory board member: BMS, Merck, Ipsen, Novartis, Pfizer, Pierre Fabre, Sanofi, Astellas. Research grant (not related to this paper): Pfizer. DP: Consultant and\/or advisory board member: BMS, Amgen, Pierre Fabre. EK: Consultant and\/or advisory board member: BMS, Novartis, Merck, Pierre Fabre. Research grant (not related to this paper): BMS. All paid to institution. MF: Research grants (paid to institution): Roche Nederland B.V., Daiichi Sankyo, Abbvie, Gilead Sciences Netherlands B.V., Astellas Pharma B.V. BR: Honoraria for lectures, SABs and consultancy (none related to the products or the aim of the described study): Amgen, Aptitude Health, AZ, BMS, Clinigen, IQVIA, MSD Oncology, Nvt, Pfizer, Roche. PR: Honoraria for lectures and Advisory Board from BMS, MSD Oncology, Novartis, Pierre Fabre, Roche. SS: Head of department, >\u2009150 agreements with external parties (paid to institute). Chair of Centre for Personalised Cancer Treatment (CPCT). Member of Supervisory board (paid to institute): SkylineDx. Patents: On assays detecting CECs, EpCAM-neg CTCs, CTC-ARv7 detection and outcome to cabazitaxel. JH: Research grants: Amgen, BMS, MSD, Novartis and Neon Therapeutics. Consultancy fees: AIMM, Achilles Tx, Amgen, AZ, Bayer, BMS, GSK, Immunocore, Ipsen, MSD, Merck Serono, Neon Tx, Neogene Tx, Novartis, Pfizer, Roche\/Genentech, Sanofi, Seatlle Genetics, Third Rock Ventures, Vaximm. AV: Consultant and\/or advisory board member: BMS, MSD, Merck, Ipsen, Eisai, Pfizer, Novartis, Pierre Fabre, Sanofi, Roche. All other authors declare no potential conflict(s) of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"323"}}